Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes

Journal of Clinical Pharmacology

Volumn 45, Issue 6, 2005, Pages 690-694

  Uno, Tsukasa ^a   Yasui Furukori, Norio ^b   Takahata, Takenori ^b   Sugawara, Kazunobu ^a   Tateishi, Tomonori ^b  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

CYP2C19; Grapefruit juice; Lansoprazole

Indexed keywords

5 HYDROXYLANSOPRAZOLE; CYTOCHROME P450 2C19; DRUG METABOLITE; LANSOPRAZOLE; LANSOPRAZOLE SULFONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; FOOD DRUG INTERACTION; GENETIC VARIABILITY; GENOTYPE; GRAPEFRUIT JUICE; HUMAN; MALE; NORMAL HUMAN;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BEVERAGES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRUS PARADISI; CROSS-OVER STUDIES; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PLANT EXTRACTS; WATER;

EID: 18844373643     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005275430     Document Type: Article

References (10)

1. Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Saf. 1998;18:251-272.
2. Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur J Clin Nutr. 2004;58:1-9.
3. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994;48:404-430.
4. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996;277:805-816.
5. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13:27-36.
6. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004;44:1223-1229.
7. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-598.
8. Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T. Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B. 2005;816:309-314.
9. Tassaneeyakul W, Vannaprasaht S, Yamazoe Y. Formation of omeprazole sulfone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br J Clin Pharmacol. 2000;49:139-144.
10. Gerloff J, Mignot A, Barth H, Heintze K. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol. 1996;50:293-297.